13 February 2016

Sinclair IS Pharma cuts loss 

Robert Tyerman

Recently-merged Sinclair IS Pharma (SPH.L) has cut annual losses 31 per cent to £11.7 million and launched an Asia-Pacific marketing drive. The AIM-quoted company, which specialises in oral health, dermatology and wound care, increased turnover 19 per cent to nearly £33 million in the year to June.

Steered by entrepreneurial chief executive Chris Spooner, Sinclair, whose losses before exceptional items rose 14.5 per cent to £5.8 million, achieved several product launches last year. The company introduced its Autopiclair eczema and dermatitis cream into France, a market which returned to growth last year with a 21 per cent turnover gain to £12.5 million, and took its Kelo-cote scar reduction formulation into several European markets.

Outgoing chairman John Gregory says the merger of Sinclair Pharma with IS Pharma should lead to annual cost savings of £1 million and has already started to pay off more positively, as with a marketing agreement for the company's Episil treatment for oral mucositis pain. Grahame Cook, already a Sinclair director, will now chair the company, which has already launched two dermatology products in seven Asia-Pacific countries under its partnership with Singapore-based Invida Holdings, a leader in commercialising bio-pharmaceutical and healthcare products in the region.

Sinclair, which ended the financial year with £5 million cash, now has a 'bio-film busting' mouthwash for sale in the USA under the PerioShield banner through an agreement with Sunstar Americas and has several new products in the pipeline. Highlighted by Growth Company Investor at 28p last autumn, Sinclair shares have eased to 24p, valuing the company at £93.3 million, but could still outperform some sector peers over the medium term.

Tags: AIM market, Asia-Pacifuyc, Autopiclair, Chris Spooner, Dermatology, Wound care

Cash Shells 2015

Published in September 2015 this annual research report provides a comprehensive overview of cash shells on the Main Market, AIM and PLUS landscape. Order your copy today

 

Superb investment toolkit for private investors

SharePad is the new web-based service from ShareScope. Easier to use and more powerful. Perfect for tablets, Macs and Windows PC. Covers ALL your investment requirements.

Growth Company Investor: free trial

Since 2008, our share tips outperformed the benchmark by 281%. Take a free trial and get access to our recommendations today. Start free trial now.

Directors' Pay on AIM 2015

The most comprehensive review of AIM directors' pay available, and this year includes a record sample of 1000+ AIM-quoted companies. The full report is available to order for £385 + VAT. Click here for more info

 

Latest small-cap and growth company news

Daily coverage of small-cap company stocks on London's junior markets AIM and PLUS, breaking news, stock research and latest share price information for investors. Full sector coverage with all the latest news on smaller listed companies, updated several times a day with financial reports, trading statements and links to further web resources.

Popular News

Latest News

Gresham brings private equity expertise to small listed stocks

There are many smaller company funds out there; but the new management of Gresham House Strategic (AIM: GHS) is trying to stand out from the crowd by bringing a ‘private equity’ approach to the public market arena. For investors who supplement their own ‘DIY’ stock picking with selected funds, GHS could be an interesting option.

Diurnal to profit from orphan drugs

Drug developer Diurnal (AIM: DNL) joined AIM a couple of days before Christmas. It already has one product in final phase III clinical trials and another due to start them shortly. So revenue generation at Diurnal should be a lot closer than at many junior biotechs. If all goes according to plan lead product Infacort should hit the market in 2018.

Forbidden focuses on selling

Forbidden Technologies (AIM: FBT) has been around a long time but has failed to generate much in the way of revenues, despite having a product that sounds like it should be a winner. There were board changes last year and new CEO Aziz Musa is shifting resources towards selling and away from technological development. This has to be the right strategy and we should find out if it’s working as this year unfolds.

Wash those nits right out of your hair!

Tyratech (AIM: TYRU) offers a compelling product proposition. Controlling bugs and parasites using conventional pesticides is both harmful to the environment and ineffective. Over the years insects have built up resistance to many of the chemicals used to kill them. So Tyratech’s natural products are not only safer but also a lot more effective than the competition. 

Angling for a cancer breakthrough

Results from medical device manufacturer Angle (AIM: AGL) showed its innovative Parsortix system to be nicely on track. The first commercial sales for research use have just been made and three leading cancer centres are moving forward with trials that will support its clinical use in the diagnosis of ovarian cancer.

2016 Quoted Company Award Winners announced

The 12th annual Grant Thornton Quoted Company Awards took place this week at the Natural History Museum in London. This prestigious event is organised by Growth Company Investor and is a celebration of the success and achievements of the UK’s smaller company sector. We published the shortlisted nominees for each award category earlier in January; so read on to see who the winners were...

More News